Purpose: We attempted to identify any parameter that could possibly lead to a successful treatment outcome after transurethral microwave thermotherapy.
Microwave heating of the prostate is a fascinating ap proach to the treatm ent of voiding disturbances in patients with benign prostatic hyperplasia (BPH).1"3 There are 2 basic concepts: hyperthermia in which the prostatic tem perature is not allowed to exceed 45C, and therm otherapy in which the target tem perature is greater th an 45C.4-5 A recent multicenter study showed th at hypertherm ia seems likely to be ineffective in the treatm ent of BPH and, thus, not to be recommended. 6 Thermotherapy applies high power microwave energy deep within the lateral pro static lobes. The results of transure thral microwave thermotherapy are promising. It is pre sumed that clinical benefit is achieved by a small decrease in adenoma volume and the destruction of certain specific cell types that have some role in the development of bladder outlet obstruction. The clinical improvement has been shown not to be due to a placebo effect or the result of the associated urethral instrumentation in randomized trials of transure thral microwave thermotherapy versus a sham procedure.3*7 However, the criteria currently used for inclusion do not prevent a high variability in term s of clinical response to transurethral microwave thermotherapy and treatm ent out come is difficult to forecast in the individual patient.
Clinical experience has shown th at significant improve ment of subjective and objective parameters of disease sever ity is achieved in a subgroup of treated patients/3»5»8 Patient parameters at entry and treatm ent parameters have been Editor's Note: This article is the fourth of 5 published in this issue for which category 1 CME credits can be earned.^ In structions for obtaining credits are given w ith the questions on pages 1910 and 1911. investigated in different series for possible correlation with treatm ent outcome. For patient selection, the specific type and grade of obstruction at screening were correlated signif icantly with the response rate in a m ulticenter European study.9 Analysis of different treatm ent param eters that are currently monitored during microwave treatm ent to date has failed to identify any difference between treatm ents leading to successful outcome and those producing no change for the individual patient. More recently, analysis of patients under going invasive thermometry of the prostate during treatm ent suggested a significant correlation between the amount of heat induced within the gland and flow rate improvement. 10 We investigate further patient treatm ent profiles to iden tify any param eter th a t could possibly lead to a successful treatm ent outcome. Digital records of the microwave tre a t ments from a large series of patients undergoing microwave therapy at 17 different prostate centers worldwide constitute the m aterial for the study.
PA TIEN TS AND M ETHODS
D ata from BPH patients undergoing microwave thermo therapy at 17 different hospitals were collected. The same instrum ent and treatm ent software were used a t the various centers, and treatm ents were performed according to a com mon study protocol. Treatm ent was given on an ambulatory basis and the method has been described in detail previous ly.11 A representation of a treatm ent session, the position of the catheter and rectal probe, and a treatm ent profile are demonstrated in figure 1 . During transurethral microwave therm otherapy the microwave energy is emitted to the pros tate resulting in heat. To prevent damage to ureth ral mucosa or the rectal wall, 1 therm al sensor is positioned in the treatm ent device and 3 sensors are placed in the rectal probe to monitor the urethral and rectal wall tem peratures. When the maximum allowed tem perature is detected by 1 of these sensors an alarm automatically interrupts the treatm ent. Therapy is resumed when the tem perature decreases to a certain level. F ig. 1. P o sitio n of 3 re c ta l te m p e r a tu r e s e n s o rs a n d u r e th r a l s e n so r in c a th e te r . C u rv e s r e p r e s e n t t e m p e r a t u r e r e a d in g s o f each se n s o r. D o tte d lin e is u r e t h r a l c u rv e a n d 3 c o n tin u o u s lin e s a re re c ta l te m p e r a tu r e cu rv es, G r a p h b o x es r e p r e s e n t a m o u n t of e n e rg y g e n e ra te d (w atts).
Screening consisted of a patient history with the MadsenIversen symptom score, physical examination with digital rectal examination of the prostate, hematology and blood chemistry studies, including prostate specific antigen (PSA) measurements, electrocardiography, chest x-ray, kidney and bladder ultrasound imaging or excretory urography, transre ctal ultrasound of the prostate and uroflowmetry (twice) with measurements of post-void residual volume using ultra sound. All patients studied were candidates for transurethral resection of the prostate and had a Madsen-Iversen symptom score of 8 or more, maximum flow rate 15 ml. per second or less and post-void residual volume 250 ml. or less. Patients were excluded from the trial because of an obstructive pros tatic middle lobe, complications of BPH, suspicion of prostate cancer, presence of any condition th at could interfere with bladder dynamics and patient compliance to the protocol.
Each center was asked to provide case record forms and copies of the treatm ent computer files of at least 10 respond ers and 10 nonresponders to microwave thermotherapy. Re sponders were identified by a Madsen-Iversen symptom score of 3 or less, or 50% or greater decrease at month 6, a maxi mum flow rate of 15 ml. per second or more, or 50% or greater improvement and a post-void residual volume of 50 ml. or less or 50% or greater improvement at 6 months. Nonre sponders were identified by a Madsen-Iversen symptom score of 8 or more or 50% or less improvement, a maximum flow rate of 10 ml. per second or less, or 20% or less improvement, and a post-void residual volume of 200 ml. or more, or 50% or less decrease at 6 months. At each center data were derived from consecutive series of patients satisfying the described criteria.
Followup visits, including symptom evaluation by MadsenIversen symptom score, flow rate measurements by free flow uroflowmetry and residual urine measurement by ultra sound, were scheduled a t 1, 3 and 6 months after treatment. Blood samples were collected at selected sites at 1 day, and 1 and 12 weeks after thermo therapy. Quality data control included survey of the received case record forms and treatm ent files. Only patients with complete data bases were considered evaluable for analysis. Data collected from case record forms and retrieved from treatm ent files were entered in a computer file and analyzed by a statistical program*
RESULTS
Of 292 patients evaluable for analysis 136 were responders and 156 were nonresponders. Analysis of patient parameters at screening showed no significant difference between the 2 groups (table 1). Changes in Madsen-Iversen symptom score, maximum flow rate and post-void residual volume are pre sented in figure 2, Responders showed an average improve ment of 76% for Madsen-Iversen symptom score and an in crease in maximum flow rate of 82%, with a decrease of 37% in post-void residual volume (table 2) . Nonresponders had an average decrease of 27% for symptom score, an actual de crease in flow rate of 5% and only a decrease of 14% in post-void residual volume.
Screening plasma levels of PSA were comparable between the 2 groups, Heat produced by microwave thermotherapy in the prostate gland is responsible for the observed increase in PSA level. Interestingly, at week 1 significantly higher val ues were measured in responders (+371%) compared to non responders (+176%). PSA values at 3 months were again comparable between the 2 groups and did not differ signifi cantly from baseline ( fig. 3) .
Different parameters derived from digital records of the microwave treatm ents were analyzed (fig. 4) . The amount of energy released during treatm ent, measured as total energy dose, average dose and maximum power output, was signif icantly different in the 2 groups. The higher amount of en ergy released in the responder group resulted in a higher temperature at the level of the urethra. The number of ure thral alarms was greater in responders versus nonre sponders but the difference was not significant (fig. 5 ). Not withstanding a higher energy release in responders, temperatures recorded at the level of the rectal wall were comparable in the 2 groups. Nevertheless, fewer rectal alarms were observed in responders compared to nonre sponders. Fig. 3 . Changes in PSA level (ng./ml.) between responders and nonresponders at baseline, and 1 day, 7 days and 3 months after treatment.
DISCUSSION
Variance analysis of data obtained has shown how our patient population did not differ significantly among the various sites and it is comparable with the BPH population enrolled in our previous studies. The use of 2 discrete popu lations of responders and nonresponders instead of a single group was designed to achieve a balance between the 2 groups, which is otherwise dependent on patient selection at the individual sites. Moreover, it is easier to perform such an analysis to determine treatm ent param eters that predict out come of treatment. The outcome of therm otherapy has been shown previously to be variable between different sites.3»5'7'a-12 To identify selection criteria th at could possibly predict successful tre a t m ent outcome, a large series of patients was evaluated ac cording to the response to treatm ent. Responder and nonre sponder characteristics at screening were not statistically different, which further supports a previous supposition from our group th at currently only baseline urodynamic param e ters can predict clinical outcome from microwave treatm ent.9 Provided the 2 groups of patients were comparable at base line, a different microwave treatm ent profile could have been responsible for the different outcome in the 2 populations. The treatm ent profile reflects the energy delivered to the prostate, and depends on the num ber of the rectal and ure thral alarms ( fig. 1 ). The alarm s result in a safe treatm ent but they may lim it the emission of microwave energy. In view of the results achieved with higher energy levels, we believe th a t the safety of treatm ent obviously interferes with effi cacy. One cannot have high tem peratures within the prostate using low power levels. 10 We know th a t the am ount of heat produced within the prostate is correlated with objective clinical outcome but such param eters are not available in this series. Nevertheless, we still have an indirect m easure of intraprostatic tem peratures, which is given by the elevation of PSA on the days following tran su reth ral microwave th er motherapy. We do not know whether epithelial cell damage is of any importance in the clinical response to microwave ther apy but it is certainly 1 of the 3 major cellular components of BPH. Interestingly, the variation of the PSA level within 1 week after treatm ent was significantly different in the 2 groups. Variation among the individual patients is high and reflects the different response of the individual prostate to microwave treatm ent, which we observed in previous stud ies. The kinetics of the PSA increase are outside the objec tives of our study but they certainly deserve attention in the future. The concept was confirmed in a recently conducted placebo controlled study. 3 The key questions are why some patients achieve a higher intraprostatic tem perature th an others and whether this is dependent on differing tissue architecture and blood supply in some prostates. Answering such questions will signifi cantly influence patient selection and the design of new treatm ent software in the future.
Analysis of different treatm ent param eters has shown that the amount of energy released during treatm ent differs sig nificantly in the 2 groups and more energy was delivered in responders compared to nonresponders. The observation was confirmed by the evaluation of 3 separate parameters: max imum power output during treatm ent, and total and average energy doses. Interestingly, the energy applied cannot be related to prostate size. W hat happened to this greater amount of energy released into the prostate of patients who did well? A higher energy dose produced a higher urethral tem perature, which is not evident when examining the peak urethral temperature achieved during treatm ent but it was clear if we note the maximum urethral tem perature sustained for a t least 3 min utes. A higher urethral tem perature has, of course, trig a greater number of urethral alarms, although the difference between the 2 groups was not significant because of the high variability of this param eter in different treatm ents (0 to 150). Transient interruption of microwave emission seems not to be detrimental to treatm ent outcome or the total en ergy dose. Therefore, where is all this energy going? The flux of energy emitted by the microwave antenna passes through the prostate from the urethra to the rectum. As the irradiative energy is absorbed by tissue it is transformed into heat energy and the tem perature increases. When temperatures increase vasodilatation occurs creating a heat sink, which may carry away significant amounts of heat. If irradiative energy is largely absorbed by pro static tissues then rectal temperature cannot increase (by lack of energy) and, conse quently, we expect fewer rectal alarms. Interestingly, this is what happened in the responder group. Lower temperatures were measured in the rectal wall of these patients and fewer alarms were recorded. A higher energy dose with lower rectal tem perature may be dependent on 2 different phenomena: either a higher energy absorption by the prostate tissue w ith a high intraprostatic temperature or a higher energy dissipation from a major blood supply with little tem perature increase within the gland. Because patients with a higher energy deposition and lower rectal tem peratures have a more successful treatm ent outcome, better energy deposition is more likely to be respon sible for fewer rectal alarms observed in responders.
CONCLUSIONS
None of the baseline param eters used within our study was able to define the ideal patient for and predict the result of treatment. Changes in PSA levels and energy absorption of the prostate merely reflect the heterogeneity of the disease and variability of outcome to this treatm ent modality. Tissue architecture of the prostate gland and its relative blood sup ply might have a role in determining the outcome of micro wave heating.12 Investigation of possible correlations among these parameters might be im portant to understand the mechanism of therapeutic effect of microwave heating on BPH, resulting in more efficient h eat induction of the pros tate.
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